Mitsubishi Tanabe Pharma Corp. Newsletter
-
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
09 Dec 2025 23:26 GMT
… ORS (EDARAVONE ORAL): MITSUBISHI TANABE PHARMA CORPORATION
13
Emerging ALS Drugs
13.1
Key Competitors … , Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel …
-
Tanabe Pharma shifts gears for Bain-backed future, dropping Mitsubishi moniker after $3.3B deal
02 Dec 2025 03:12 GMT
Mitsubishi Tanabe Pharma has undergone a rebrand. … deal to buy the Japanese drugmaker from its parent company, … forward, the Japanese drugmaker will operate as Tanabe Pharma. The new … the modern drugmaker when it merged with Mitsubishi Pharma in 2001 …
-
Generic Musculoskeletal Disorders Drugs Market to Reach USD $0.08 Billion by 2029 at 6.9% CAGR
24 Nov 2025 10:45 GMT
… market prominence. For instance, Mitsubishi Tanabe Pharma Corporation, a pharmaceutical firm based in Japan … ) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy
Subsegments:
1) By …
-
Mitsubishi Tanabe Pharma America to Present New Data on Investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
03 Oct 2025 13:43 GMT
… Twitter), Facebook and LinkedIn.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC) is one … ;precision medicine" to provide drugs with high treatment satisfaction and …
-
Sanofi Korea transfers MS drug Aubagio rights to Mitsubishi Tanabe
15 Sep 2025 09:46 GMT
Sanofi Korea has granted Mitsubishi Tanabe Pharma Korea exclusive rights to market … arrangement, effective Sept. 1, gives Mitsubishi Tanabe control of sales and marketing …
-
Dewpoint receives FDA orphan drug designation for DPTX3186
30 Oct 2025 12:51 GMT
… recently opened its investigational new drug application for the oral … review processes.
Dewpoint’s drug discovery pipeline encompasses several therapeutic … company operates through partnerships with Mitsubishi Tanabe Pharma, Bayer and Novo Nordisk.
…
-
FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
29 Oct 2025 14:00 GMT
… art integrated technology underlies a drug discovery pipeline that spans … with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries … and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide …
-
2025 pharma M&A surges to $70 billion in major deals
11 Oct 2025 01:46 GMT
… ); and Bain Capital carved out Mitsubishi Tanabe Pharma for $3.3B in a … , deal flow, deal premiums, drug development, drug pricing, efimosfermin, efruxifermin, Eli Lilly …
-
Pertussis Market Analysis and Forecast Report 2025-2035, Competitive Profiles of GlaxoSmithKline, Mitsubishi Tanabe Pharma, Sanofi, Sun Pharmaceutical, & ILiAD Biotechnologies. - ResearchAndMarkets.com
25 Jul 2025 14:54 GMT
DUBLIN--(BUSINESS WIRE)--Jul 25, 2025--
×
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
kAm%96 8=@32= A6CEFDD:D >2C<6E :?4=F56D G2C:@FD G244:?6 7@C>F=2E:@?D DF49 2D H9@=6\46== G244:? …
-
Mitsubishi Tanabe Pharma forms targeted alpha therapy collaboration in Japan
11 Jul 2025 13:00 GMT
Cancer
Mitsubishi Tanabe Pharma Corp., Veneno Technologies Co. Ltd. and Alpha Fusion Co. Ltd. have initiated a joint research collaboration in Japan to develop cancer drugs using targeted alpha therapy (TAT).
BioWorld Science Collaboration Cancer
About
© 1995-2025